MTOR and hepatocellular carcinoma: Finally, although M2BPGi treatment enhanced the proliferation of HCC cells (Fig. 3a), the tumour-promoting effects of M2BPGi were cancelled by treatment with the representative mTOR inhibitor rapamycin (Fig. 5e).